Growth of the biopharmaceutical market is going to create critical shortages in protein manufacturing capacity with severe consequences for pharmaceutical companies' ability to deliver products and meet rising market expectations. Companies whose pipelines are heavily reliant on expression systems with limited capacity are particularly vulnerable and should now be making strategic make/buy/collaborate decisions. Indeed, in the short term as capacity tightens, contract manufacturing organizations will gain greater leverage, enabling them to negotiate more strategic business relationships with higher financial returns. In the longer term, however, innovator companies are looking beyond cell culture to alternative technologies such as transgenic animals as a future production platform, in part, because they provide greater flexibility.
by Roland Andersson and Richard Mynahan
Significant investment in biotechnology over the past few years is paying off. Though the pharmaceutical industry will grow 7-8% annually...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.